SPECIFIC GENETIC MARKETS FOR CYTOGENETICALLY DEFINED ACUTE MYELOID LEUKAEMIA

摘要

A method of assigning a patient having or suspected of having acute myeloid leukaemia (AML) to a cytogenetically defined AML class, the method comprising providing a sample from the patient, using gene expression profiling to determine the expression level of at least one informative gene in the sample, and using the at least one determined expression level to assign the sample to an AML class. The invention also includes a method of assigning a patient having or suspected of having AML to an AML class, comprising providing a sample from the patient, determining the expression level of at least one informative gene selected from the genes listed in Table 1 or Table 2 or Table 3 in the sample, and using the at least one determined expression level to assign the sample to an AML class.